Metex

Methotrexate, the active ingredient in Metex, is an antimetabolite presented as a solution for injection for intramuscular, intravenous, and subcutaneous use. It is employed to manage rheumatoid arthritis, severe psoriasis, certain leukemias and lymphomas, and gestational trophoblastic disease in appropriate patients.

GNH USA supplies Metex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Its distribution network ensures timely delivery across Europe, Asia, Africa and the Americas.

Methotrexate is used in several disease categories, primarily autoimmune disorders and certain malignancies. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: improves skin lesions and decreases disease severity. - Acute lymphoblastic leukemia: induces remission by inhibiting rapidly dividing leukemic cells. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination chemotherapy. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Mouth sores (stomatitis) - Mild liver enzyme elevation - Low white blood cell count (leukopenia) Serious or Rare Side Effects: - Severe liver toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Renal impairment - Severe bone marrow suppression (pancytopenia) - Life‑threatening infections due to immunosuppression

When prescribing methotrexate, clinicians should observe several safety measures to minimize risk. - Baseline testing: obtain liver function, renal function and complete blood count before initiation. - Monitoring: repeat laboratory tests regularly to detect hepatotoxicity or marrow suppression. - Contraindications: avoid use in pregnancy and during breastfeeding. - Drug interactions: review concomitant medications that may increase toxicity, such as NSAIDs or penicillins. - Patient counseling: advise patients to limit alcohol intake and report signs of infection promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several agents that can alter its efficacy or increase toxicity. Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can raise methotrexate serum levels and risk renal toxicity. - Proton pump inhibitors (e.g., omeprazole): may impair renal clearance and increase toxicity. - Trimethoprim‑sulfamethoxazole: synergistic bone‑marrow suppression. Moderate Interactions (Monitor Closely): - Penicillins (e.g., ampicillin): can reduce renal excretion of methotrexate. - Sulfonylureas: may enhance hypoglycaemic effect. - Live vaccines: risk of infection due to immunosuppression. - Alcohol: potentiates hepatotoxicity.